Treating Alzhemer’s disease with an NIDDM drug: Metformin, the widely used drug in the treatment of T2DM, decreases Tau expression via up regulation of its target gene, 19/October/2014, 21.54

Treating Alzhemer’s disease with an NIDDM drug: Metformin, the widely used drug in the treatment of T2DM, decreases Tau expression via up regulation of its target gene, 19/October/2014, 21.54

Treating Alzhemer’s disease with an NIDDM drug: Metformin, the widely used drug in the treatment of T2DM, decreases Tau expression via up regulation of its target gene, 19/October/2014, 21.54 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L. Treating Alzhemer’s disease  with an NIDDM drug: Metformin, the widely used drug in the treatment of T2DM, decreases Tau expression via up regulation of its target gene, 19/October/2014, 21.54, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance:  It has been shown that decreasing the expression of Tau protein alleviates the pathogenic symptoms-associated with Alzheimer’s disease. This study suggests, for the first time, that Metformin decreases the expression of Tau protein. Thus, pharmacological formulations encompassing “Metformin or its analogues” can be used to treat patients suffering from Alzheimer’s disease and tauopathies.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Share
Start Typing